While we await results from our initial proof of efficacy study this summer in Long QT Syndrome, we are able to accelerate a number of pipeline initiatives thanks to this new investment from IQ.

Data from this study demonstrated escalating doses of LQT-1213 up to seven days were well tolerated with good oral bioavailability, favorable pharmacokinetics profile, and no significant adverse events

Ms. Koomey brings an impressive depth of experience in product commercialization, launch and marketing execution, which will be crucial as Thryv advances its development programs in rare arrhythmias such as Long QT Syndrome and advanced cancers.

Two fireside chats by Mr. Paul F. Truex CEO on Thryv’s progress with the development of a number of highly potent SGK1 inhibitors for all major forms of Long QT Syndrome, atrial fibrillation and resistant cancers.

Results of SGK1 Inhibition in Patient- and Genotype Specific Re-Engineered Heart Cells with Congenital Long QT Syndrome and a model of Drug-Induced QT Prolongation to be presented at the AHA Scientific Sessions 2022 taking place November 5-7, 2022, in Chicago

We are pleased to appoint Dr. Debra Odink to President & CDO, and Dr. Shi Yin Foo to our Board. Both individuals bring impressive depth of development and company building expertise, which will be crucial as Thryv moves into clinical trials later this month.

We are excited to announce the evolution of our portfolio to include treatments for resistant and rare cancers. The new name, Thryv Therapeutics, embodies our commitment to relentlessly pursue therapies which provide lifelong benefits to patients, families, doctors, nurses and stakeholders.

Patient identification and enrollment for our pivotal LQTS clinical trial is a strategic focus of LQTT. Mr Wight’s expertise will play a critical role in guiding our clinical and regulatory strategies.

Dr. Donald McDonnell of Duke University School of Medicine will evaluate LQTT SGK1 inhibitors as potential treatment for people with resistant prostate and breast cancer.

The EJP RD is a collaboration of over 130 institutions from 35 countries, working together to create a comprehensive ecosystem between research, care, and medical innovation. This award is significant as we advance SGK1 inhibitors.

Dr. Campeau will collaborate with Dr. McDonnell and his research team at Duke University to evaluate SGK1 inhibitors as potential treatments for people with breast and prostate cancer.

A major objective after our Series A financing, has been to enrich our Board with experienced, respected and highly accomplished drug development executives as we advance our clinical programs.

LQTT has completed US$19 million Series A financing led by Amplitude Ventures and included new investments from existing investors. We’re advancing a series of in-licensed compounds discovered and developed by Sanofi S.A. that inhibit SGK1.

Amplitude Ventures exceeded their CAD$200M raise target and attracted investment from across the country and internationally. Amplitude is an early seed investor of LQTT.

Marc-Olivier Sirard, CPA, senior investment advisor at Fonds de solidarité FTQ, and Dr. Saumya Das, PhD, MD, Director of the Resynchronization and Advanced Cardiac Therapeutics Program at Massachusetts General Hospital, join our board of directors.

LQT Therapeutics announces research collaboration with the Mayo Clinic in Rochester, Minnesota to evaluate novel pharmacologic treatments for LQTS, an arrhythmia associated with a prolonged QT interval that can cause sudden death.

LQT Therapeutics raised up to C$1.8M seed funding led by Fonds de solidarité FTQ and other founding investors. Our aim is to develop a series of preclinical compounds as new treatment options for Long QT Syndrome and other arrhythmias.